克林沙星对来自北美10个中心的当代临床分离菌株的体外活性。
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
作者信息
Fuchs P C, Barry A L, Brown S D
机构信息
The Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA.
出版信息
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
Abstract
Clinafloxacin was more active than ciprofloxacin against 4,213 aerobic and facultative anaerobic bacterial isolates from 10 medical centers, as tested by broth microdilution and disk diffusion methods. The percentage of 201 anaerobes susceptible to clinafloxacin by broth microdilution was comparable to cefoxitin. Our data support the proposed disk diffusion interpretive criteria for aerobic bacteria with 5-microg clinafloxacin disks.
摘要
通过肉汤微量稀释法和纸片扩散法检测发现，对于来自10个医学中心的4213株需氧菌和兼性厌氧菌分离株，克林沙星比环丙沙星更具活性。通过肉汤微量稀释法检测，201株厌氧菌对克林沙星的敏感率与头孢西丁相当。我们的数据支持了针对5微克克林沙星纸片对需氧菌的纸片扩散法解释标准。
相似文献
1
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
2
In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
J Antimicrob Chemother. 1997 Aug;40(2):205-11. doi: 10.1093/jac/40.2.205.
3
In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
Diagn Microbiol Infect Dis. 2000 Dec;38(4):243-53. doi: 10.1016/s0732-8893(00)00198-x.
4
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
J Antimicrob Chemother. 1998 Jun;41(6):605-14. doi: 10.1093/jac/41.6.605.
5
Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
Diagn Microbiol Infect Dis. 1999 Sep;35(1):81-8. doi: 10.1016/s0732-8893(99)00020-6.
6
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Antimicrob Agents Chemother. 1998 May;42(5):1269-73. doi: 10.1128/AAC.42.5.1269.
7
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):305-9. doi: 10.1007/s100960050284.
8
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
J Antimicrob Chemother. 1993 Dec;32(6):877-84. doi: 10.1093/jac/32.6.877.
9
Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
Diagn Microbiol Infect Dis. 1995 Jan;21(1):33-45. doi: 10.1016/0732-8893(94)00087-d.
10
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Chemotherapy. 1993;39(1):32-5. doi: 10.1159/000238970.
引用本文的文献
1
A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
2
Drug interactions with clinafloxacin.
Antimicrob Agents Chemother. 2001 Sep;45(9):2543-52. doi: 10.1128/AAC.45.9.2543-2552.2001.
3
Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.
Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42. doi: 10.1128/AAC.45.9.2536-2542.2001.
4
Pharmacokinetics of clinafloxacin after single and multiple doses.
Antimicrob Agents Chemother. 2001 Sep;45(9):2529-35. doi: 10.1128/AAC.45.9.2529-2535.2001.
5
In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.
Antimicrob Agents Chemother. 2001 May;45(5):1553-7. doi: 10.1128/AAC.45.5.1553-1557.2001.
6
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
Ann Surg. 2001 Jan;233(1):79-87. doi: 10.1097/00000658-200101000-00013.
7
Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.
Antimicrob Agents Chemother. 2000 Jun;44(6):1710-2. doi: 10.1128/AAC.44.6.1710-1712.2000.
8
In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.
Antimicrob Agents Chemother. 2000 Apr;44(4):1102-7. doi: 10.1128/AAC.44.4.1102-1107.2000.
9
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
Drugs. 1999;58 Suppl 2:29-36. doi: 10.2165/00003495-199958002-00006.
10
Activity of newer fluoroquinolones in vitro against gram-positive bacteria.
Drugs. 1999;58 Suppl 2:23-8. doi: 10.2165/00003495-199958002-00005.
本文引用的文献
1
Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.
Antimicrob Agents Chemother. 1998 Feb;42(2):428-30. doi: 10.1128/AAC.42.2.428.
2
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.
J Antimicrob Chemother. 1996 Dec;38(6):1023-9. doi: 10.1093/jac/38.6.1023.
3
In vitro susceptibility of anaerobes to quinolones in the United States.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S2-8. doi: 10.1093/clinids/23.supplement_1.s2.
4
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Chemotherapy. 1996 Jul-Aug;42(4):235-9. doi: 10.1159/000239449.
5
In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.
Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7. doi: 10.1128/AAC.39.9.2123.
6
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. doi: 10.1128/AAC.38.2.369.
7
In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
J Antimicrob Chemother. 1994 Oct;34(4):579-84. doi: 10.1093/jac/34.4.579.
8
Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Diagn Microbiol Infect Dis. 1995 Jan;21(1):27-31. doi: 10.1016/0732-8893(94)00143-k.
9
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Diagn Microbiol Infect Dis. 1995 Apr;21(4):209-13. doi: 10.1016/0732-8893(94)00061-z.
10
Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
Antimicrob Agents Chemother. 1995 Jul;39(7):1606-8. doi: 10.1128/AAC.39.7.1606.
Zotero 插件